Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-15 02:01 UTC

BIOMED PULSE

September 15, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the DRC, with sustained cross-border transmission into Uganda still active. [1]

The overall mood is elevated concern: a historic hemorrhagic fever crisis dominates the outbreak landscape while longevity science edges forward on senescence-targeting therapies and aging-biology trials.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (DRC AND UGANDA) - LARGEST EBOLA OUTBREAK ON RECORD

  • As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has spread to 61 health zones across six provinces: Bas-Uelé, Haut-Uelé, Ituri, North Kivu, South Kivu, and Tshopo, with one newly added zone, Kayna, in North Kivu. [1]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, and has been declared by WHO as the largest Ebola outbreak ever reported in the DRC, expanding faster than any previous Ebola outbreak. [2]
  • As of July 15, 2026, cumulative confirmed cases stood at 2,124 with 828 deaths; by August the pace of spread was described as intense and characterized by sustained transmission in multiple provinces. [3]
  • Cross-border transmission into Uganda was confirmed as early as May 2026, when both countries formally declared outbreaks following confirmation of Bundibugyo virus disease in both nations. [4]
  • CDC mobilized an international response starting May 17, 2026, and enhanced airport screening was activated at Washington-Dulles International Airport on May 21 and expanded to Atlanta on May 23, 2026. [5] [6]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO first reported the Andes hantavirus (ANDV) cluster linked to the cruise ship M/V Hondius on May 2, 2026; as of the fifth Disease Outbreak News update (July 2, 2026), additional confirmed cases had been added beyond the initial seven cases identified among the ship's 147 passengers and crew. [7] [8]
  • CDC provided ongoing response updates through late June 2026, with the risk to the general American public described as extremely low as of May 8, 2026. [9]

NIPAH VIRUS - INDIA

  • On June 11, 2026, the Kerala State Health Department confirmed a single laboratory-confirmed case of Nipah virus (NiV) infection in Kozhikode district; the adult male developed symptoms on May 30, 2026, was hospitalized June 10, and presented with neurological features. [10]

MEASLES - BANGLADESH

  • On April 23, 2026, Bangladesh's IHR Focal Point notified WHO of a nationwide measles surge affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries across the Americas and Africa reported 79 human yellow fever infections; transmission in the Americas persisted into 2026 following a surge in 2025.

WEST NILE VIRUS - UNITED STATES

  • CDC reported a record-early West Nile season with unusually high case counts as of July 1, 2026, and issued guidance for Americans to use mosquito bite prevention during the Independence Day holiday weekend.

ANIMAL RABIES AND HUMAN EXPOSURES - UNITED STATES

  • CDC issued a statement on September 10, 2026 noting a recent increase in animal rabies activity and associated human exposures across the United States, urging awareness and post-exposure prophylaxis uptake.

SALMONELLA AND OTHER FOOD SAFETY OUTBREAKS - UNITED STATES

  • CDC is investigating a Salmonella outbreak linked to Metabolic Meals home delivery foods, with 16 people sick across 10 states as of September 5, 2026.
  • A separate Salmonella outbreak tied to alfalfa sprouts was reported August 21, 2026, with both E. coli and Salmonella cases linked to a recalled alfalfa sprout product in a multistate investigation.
  • A Salmonella outbreak linked to jalapeños was posted August 5, 2026, with a multistate food safety alert issued by CDC.

🧬 LONGEVITY & AGING

SENESCENCE-TARGETING THERAPIES FOR SPINAL DISC DEGENERATION

  • Researchers published findings (Biomaterials, July 2026) on injectable hydrogel microspheres loaded with senescence-targeting apoptotic extracellular vesicles that reduced ferroptosis (a form of iron-dependent cell death) in nucleus pulposus cells, potentially slowing intervertebral disc degeneration.
  • A companion review (Bioactive Materials, September 2026) surveyed biomaterials for intervertebral disc regeneration, covering niche reprogramming, precision therapeutics, and structural reconstruction as a multimodal anti-aging strategy for spinal tissue.

SENESCENCE AND OSTEOARTHRITIS

  • A dual-modal antioxidant-plus-epigenetic combination strategy was shown to break the self-perpetuating senescence cycle in osteoarthritic cartilage, published in Bioactive Materials (July 2026).
  • A separate study (Bioactive Materials) described a chondrocyte-targeting tetrahedral DNA nanoparticle that improved delivery of metformin into joint cartilage and alleviated osteoarthritis in preclinical models, linking the anti-aging drug metformin to cartilage protection.

BONE AGING AND REPAIR

  • Loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells was associated with impaired fracture healing in aged mice, published in Bioactive Materials (August 2026), pointing to EGFR signaling as a druggable target in age-related bone fragility.
  • A dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis was shown to promote repair of age-related bone defects (Bioactive Materials, August 2026), combining mRNA medicine with bone geroscience.
  • A BMP-2-driven osteo-organoid was reported to retain osteogenic-support features and promote bone repair after total-body irradiation in a Bioactive Materials study (August 2026).

RADIATION-INDUCED HAIR FOLLICLE SENESCENCE

  • Ionizing radiation was found to induce senescence in dermal papilla cells by inhibiting the FOXM1-KIF20A pathway, offering a mechanistic explanation for radiation-associated hair loss and aging, published in Genes and Disease.

YOUNG PLASMA EXOSOMES AND ALZHEIMER'S DISEASE

  • Engineered exosomes derived from young plasma were studied for their potential to treat Alzheimer's disease, with the Bioactive Materials paper (August 2026) describing protein cargo relevant to neurodegeneration and aging.

LUNG CANCER BURDEN IN AGING ASIA

  • A Europe PMC study (Annals of Medicine, September 11, 2026) projected the shifting burden of tracheal, bronchial, and lung cancer in aging Asian populations through 2050, identifying structural demographic drivers including rapid population aging as key accelerants.

DEPRESCRIBING IN OLDER ADULTS

  • Two Lancet Healthy Longevity commentaries argued that deprescribing clinical trials need a rationale-first framework before choosing trial design, warning against overfitting study design to convenience rather than clinical logic for older polypharmacy patients.

HIP FRACTURE ANESTHESIA IN OLDER PATIENTS

  • A multicenter randomized clinical trial from Germany (Lancet Healthy Longevity) compared spinal versus general anesthesia for hip fracture surgery in older patients, with an accompanying editorial noting the question may now be ready for a definitive clinical answer.

URBAN EXPOSOME AND BIOLOGICAL AGING (NEW TRIAL)

  • A newly registered ClinicalTrials.gov observational study (NCT07817836, registered September 14, 2026) will evaluate how urban air pollution and lifestyle stressors affect biological aging, inflammatory pathways, oxidative stress, and DNA methylation in healthy workers in an unnamed city.

AMYLOID PET IN THE BALTIMORE LONGITUDINAL STUDY OF AGING

  • A ClinicalTrials.gov study (NCT07099053) is using amyloid PET imaging within the Baltimore Longitudinal Study of Aging to track brain amyloid accumulation over time and its relationship to cognitive decline, with a September 14, 2026 update.

💊 NEW CURES & APPROVALS

ETCAMAH (CAMIZESTRANT) - ASTRAZENECA PHARMACEUTICALS

  • AstraZeneca Pharmaceuticals received an original FDA approval (NDA220359) for Etcamah, whose active ingredient is camizestrant, an oral selective estrogen receptor degrader (SERD) intended for hormone receptor-positive breast cancer.

HYRNUO (SEVABERTINIB) - BAYER HEALTHCARE

  • Bayer Healthcare received a supplemental FDA approval (NDA219972) for Hyrnuo, containing sevabertinib, a targeted oncology agent in the kinase inhibitor class.

HANDA ONCOLOGY NDA220613

  • Handa Oncology, LLC received an original FDA approval (NDA220613); the active ingredient and full indication details were not specified in the available data.

IBRUTINIB GENERIC - HETERO LABS LTD V

  • Hetero Labs received an original ANDA approval (ANDA211182) for generic ibrutinib, a BTK inhibitor used in blood cancers including CLL and mantle cell lymphoma.

BRIVARACETAM GENERIC - ZHEJIANG JUTAI PHARMA

  • Zhejiang Jutai Pharma received an original ANDA approval (ANDA220136) for generic brivaracetam, an antiepileptic agent used in partial-onset seizures.

AMELUZ (AMINOLEVULINIC ACID HCL) - BIOFRONTERA

  • Biofrontera received a supplemental FDA approval (NDA208081) for Ameluz, a photosensitizer containing aminolevulinic acid hydrochloride used in photodynamic therapy for actinic keratosis.

🧪 CLINICAL TRIALS

ZANUBRUTINIB IN OLDER PATIENTS WITH UNTREATED CLL (NCT07739459)

  • A Phase II open-label multicenter study registered September 14, 2026, is evaluating zanubrutinib (a BTK inhibitor) in patients aged 80 years and older with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who require treatment.

DIET, EXERCISE, AND METFORMIN FOR FRAILTY IN OBESE OLDER VETERANS (NCT04221750)

  • This active trial is testing a multicomponent intervention combining diet-induced weight loss, exercise training, and metformin to treat frailty in obese older Veterans, with an updated record as of September 14, 2026.

PARK GOLF AND PREFRONTAL CORTEX IN OLDER ADULTS (NCT07807631)

  • A 36-participant randomized study (aged 65 to 85) registered September 14, 2026 is investigating whether a park golf program improves working memory and prefrontal cortex activation compared to a health education control group in community-dwelling older adults.

ONCOGERIATRIC PREHABILITATION FOR SURGICAL CANCER PATIENTS (NCT06443138)

  • A trial updated September 14, 2026 is studying prehabilitation strategies to optimize functional ability before, during, and after cancer surgery in elderly patients, addressing the high risk of postoperative complications in this population.

NEOANTIGEN-SPECIFIC T CELL THERAPY FOR HEMATOLOGIC MALIGNANCIES (NCT06904066)

  • Updated September 14, 2026, this NCI trial is using autologous T cells transduced with retroviral vectors expressing TCRs for participant-specific neoantigens to treat blood cancers including leukemias with TP53 or RAS mutations.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA SURGE - CDC REPORT

  • A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria; this data remains the most recent published national antimicrobial resistance snapshot and continues to inform 2026 clinical guidance.

CONGENITAL SYPHILIS - 12TH CONSECUTIVE YEAR OF INCREASE

  • CDC data released September 24, 2025 showed U.S. newborn syphilis cases increased for the 12th consecutive year in 2024, underscoring persistent gaps in prenatal STI screening and treatment.

LISTERIA OUTBREAK LINKED TO PREPARED FOODS - ONGOING

  • CDC expanded its Listeria monocytogenes outbreak alert linked to prepared meals on September 26, 2025, adding three new illnesses and one additional death; consumers are urged to check refrigerators and freezers for recalled products.

CDC KINDERGARTEN VACCINATION RATES - 2026 DATA

  • CDC data released August 17, 2026 show kindergarten vaccination rates remain high overall, with only a slight 0.1 percent decline in coverage, though officials noted the need for continued vigilance.

NEW WORLD SCREWWORM - CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026, marking an unusual parasitic threat requiring coordinated federal action.

BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, strengthening the nation's ability to detect imported pathogens at the border.

NOTE: BIOMED PULSE is an informational briefing grounded in official public health and research sources. Nothing here constitutes medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  9. CDC Provides Update on Hantavirus Outbreak Linked to M/V Hondi… — CDC Newsroom
  10. Nipah virus disease - India — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260915-02-v76 · 2026-09-15 02:01 UTC · pulse.uzylab.com

Read next